Inotiv, Inc. Common Stock (NOTV)

Price$0.31

Value ScoreB

Growth ScoreB

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-82.50%

Price vs S&P 500 (4W)-12.71%

VGM Score58.28

Market Capitalization$10.72M

All Metrics

Book Value / Share (Quarterly)$2.21

P/TBV (Annual)29.75x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.16%

Cash Flow / Share (Quarterly)$-0.39

Price vs S&P 500 (YTD)-60.05%

Gross Margin (TTM)22.94%

Net Profit Margin (TTM)-17.14%

EPS (TTM)$-2.52

10-Day Avg Trading Volume0.75M

EPS Excl Extra (TTM)$-2.52

Revenue Growth (5Y)53.35%

EPS (Annual)$-2.11

ROI (Annual)-12.61%

Gross Margin (Annual)23.58%

Net Profit Margin (5Y Avg)-20.64%

Cash / Share (Quarterly)$0.44

Revenue Growth QoQ (YoY)-5.37%

ROA (Last FY)-8.90%

Revenue Growth TTM (YoY)5.61%

EBITD / Share (TTM)$0.22

ROE (5Y Avg)-47.25%

Operating Margin (TTM)-9.48%

Cash Flow / Share (Annual)$-0.79

P/B Ratio0.14x

P/B Ratio (Quarterly)0.12x

Net Income / Employee (Annual)$-35,300

EV / Revenue (TTM)0.83x

Net Interest Coverage (TTM)-0.55x

ROA (TTM)-11.72%

EV / EBITDA (TTM)54.95x

EPS Incl Extra (Annual)$-2.11

Current Ratio (Annual)0.35x

Quick Ratio (Quarterly)0.18x

3-Month Avg Trading Volume0.68M

52-Week Price Return-89.79%

Revenue / Employee (TTM)$260,900

Tangible BV / Share (Quarterly)$0.57

P/S Ratio (Annual)0.02x

Asset Turnover (Annual)0.67x

52-Week High$3.32

Operating Margin (5Y Avg)-18.44%

EPS Excl Extra (Annual)$-2.11

CapEx CAGR (5Y)21.79%

Tangible BV CAGR (5Y)11.54%

26-Week Price Return-66.57%

Quick Ratio (Annual)0.23x

13-Week Price Return4.88%

Total Debt / Equity (Annual)3.00x

Current Ratio (Quarterly)0.27x

Enterprise Value$423.21M

Revenue / Share Growth (5Y)23.29%

Asset Turnover (TTM)0.68x

Book Value / Share Growth (5Y)41.79%

Revenue / Employee (Annual)$263,800

Inventory Turnover (Annual)12.27x

Pretax Margin (Annual)-17.11%

Cash / Share (Annual)$0.63

3-Month Return Std Dev180.69%

Gross Margin (5Y Avg)27.51%

Net Income / Employee (TTM)$-44,700

EBITDA CAGR (5Y)91.57%

ROE (Last FY)-50.45%

Net Interest Coverage (Annual)-0.86x

EPS Basic Excl Extra (Annual)$-2.11

P/FCF (TTM)0.92x

Receivables Turnover (TTM)7.67x

Total Debt / Equity (Quarterly)5.55x

EPS Incl Extra (TTM)$-2.52

Receivables Turnover (Annual)6.76x

ROI (TTM)-16.44%

P/S Ratio (TTM)0.02x

Pretax Margin (5Y Avg)-24.60%

Revenue / Share (Annual)$15.81

Tangible BV / Share (Annual)$0.57

Price vs S&P 500 (52W)-117.99%

Year-to-Date Return-49.12%

5-Day Price Return5.93%

EPS Normalized (Annual)$-2.11

ROA (5Y Avg)-13.33%

Net Profit Margin (Annual)-13.38%

Month-to-Date Return-1.41%

Cash Flow / Share (TTM)$-10.97

EBITD / Share (Annual)$0.77

Operating Margin (Annual)-6.02%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)30.28x

ROI (5Y Avg)-18.25%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.52

P/TBV (Quarterly)29.75x

P/B Ratio (Annual)0.37x

Inventory Turnover (TTM)11.40x

Pretax Margin (TTM)-20.84%

Book Value / Share (Annual)$3.96

Price vs S&P 500 (13W)-4.87%

Beta3.81x

P/FCF (Annual)28.20x

Revenue / Share (TTM)$14.64

ROE (TTM)-74.67%

52-Week Low$0.22

vGradeB

gGradeB

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q2 26-0.94est. -0.65

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.13

Industry Peers — R&D — Physical Sciences(15)

Symbol	Value Score	Growth Score	Momentum Score	Price
NOTVInotiv, Inc. Common Stock	B	B	D	$0.31
IQVIQVIA Holdings Inc.	C	B	B	$186.82
INCYIncyte Genomics Inc	C	A	B	$95.59
MEDPMedpace Holdings, Inc. Common Stock	D	A	B	$451.47
ICLRIcon Plc	C	C	B	$138.03
CRLCharles River Laboratories International, Inc.	D	D	B	$182.07
ABSIAbsci Corporation Common Stock	F	F	A	$6.52
NRCNRC Health Common Stock	D	D	B	$20.25
OABIOmniAb, Inc. Common Stock	D	C	A	$2.61
MXCTMaxCyte, Inc. Common Stock	C	D	C	$1.22
ONMDOneMedNet Corp Class A Common Stock	D	C	C	$0.78

About

Inotiv provides nonclinical and analytical drug development services to pharmaceutical, chemical, and medical device companies. Operating through two segments—Discovery and Safety Assessment and Research Models and Services—the company supports small molecule and biologic drug discovery while supplying specialized research models for disease-specific applications. The Research Models and Services segment generates the majority of revenue.